Patents by Inventor Charles W. Eigenbrot, Jr.

Charles W. Eigenbrot, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES
    Publication number: 20180000962
    Abstract: Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
    Type: Application
    Filed: May 10, 2017
    Publication date: January 4, 2018
    Applicant: Genentech, Inc.
    Inventors: Charles W. Eigenbrot, JR., Jagath Reddy Junutula, Henry Lowman, Helga E. Raab, Richard Vandlen
  • CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES
    Publication number: 20150017188
    Abstract: Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
    Type: Application
    Filed: January 10, 2014
    Publication date: January 15, 2015
    Applicant: Genentech, Inc.
    Inventors: Charles W. Eigenbrot, JR., Jagath Reddy Junutula, Henry Lowman, Helga E. Raab, Richard Vandlen
  • CRYSTAL STRUCTURE OF HEPATOCYTE GROWTH FACTOR ACTIVATOR COMPLEXED WITH KUNITZ DOMAIN INHIBITOR
    Publication number: 20100277473
    Abstract: The present disclosure provides crystals of and structural coordinates of Hepatocyte growth factor activator with and without bound pseudo-substrate or inhibitor. In a specific embodiment, a crystal structure of activated HGFA complexed with a Kunitz domain inhibitor is provided. The crystals and crystal structures are useful, for example, in the design and synthesis of inhibitors of HGFA.
    Type: Application
    Filed: April 9, 2010
    Publication date: November 4, 2010
    Inventors: Charles W. EIGENBROT, JR., Daniel K. Kirchhofer
  • Crystal structure of hepatocyte growth factor activator complexed with Kunitz domain inhibitor
    Patent number: 7741096
    Abstract: The present disclosure provides crystals of and structural coordinates of Hepatocyte growth factor activator with and without bound pseudo-substrate or inhibitor. In a specific embodiment, a crystal structure of activated HGFA complexed with a Kunitz domain inhibitor is provided. The crystals and crystal structures are useful, for example, in the design and synthesis of inhibitors of HGFA.
    Type: Grant
    Filed: December 9, 2005
    Date of Patent: June 22, 2010
    Assignee: Genentech, Inc.
    Inventors: Charles W. Eigenbrot, Jr., Daniel K. Kirchhofer